Pharmaceutical Intermediate CAS 100986-85-4 Levofloxacin Powder with High Quality

• Powder: Yes
• Customized: Customized
• Suitable for: Adult
• Purity: >99%
• Mf: C18h20fn3o4
• Einecs No.: 600-146-0
• Appearance: White Powder
• MOQ: 1kg
• Grade: Pharmaceutical Grade
• Test Method: HPLC
• Molecular Weight: 361.37
• Melting Point: 140.5-141.5 °c
• CAS: 100986-85-4
• Transport Package: Paper Bag or Drum
• Specification: 1kg/bag; 25kg/drum
• Trademark: Greenway Biotech
• Origin: China
• HS Code: 2942000000
• Production Capacity: 1000kg/Year

Product Description

Pharmaceutical Intermediate CAS 100986-85-4 Levofloxacin Powder with High
Quality

Product Name	Levofloxacin
Brand Name	Greenway Biotech
Purity	99%
MF	C18H20FN3O4
Appearance	White Powder
Test Method	HPLC

Description

Levofloxacin is suitable for genitourinary infections caused by sensitive bacteria,
including simple and complicated urinary tract infections, bacterial prostatitis, Neisseria
gonorrhoeae urethritis or cervicitis (including those caused by enzyme production). Respiratory
infections, including acute bronchial infections caused by sensitive Gram-negative bacilli and
pulmonary infections. Gastrointestinal infection, caused by Shigella, Salmonella, enterotoxin-producing Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus. It can also treat systemic
infections such as typhoid, bone and joint infections, skin and soft tissue infections and sepsis.

Function:

1. Levofloxacin is used to treat infections including: respiratory tract infections, cellulitis,
urinary tract infections, prostatitis, anthrax, endocarditis, meningitis, pelvic inflammatory
disease, traveler's diarrhea, tuberculosis, and plague and is available by mouth, intravenously,
and in eye drop form.

2. Levofloxacin is used for the treatment of pneumonia, urinary tract infections, and abdominal
infections. As of 2007 the Infectious Disease Society of America (IDSA) and the American
Thoracic Society recommended levofloxacin and other respiratory fluoroquinolines as first line
treatment for community acquired pneumonia when co-morbidities such as heart, lung, or
liver disease are present or when in-patient treatment is required.Levofloxacin also plays an
important role in recommended treatment regimens for ventilator-associated and
healthcare-associated pneumonia.